Cantor Fitzgerald Weighs in on Zai Lab FY2026 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Zai Lab in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings per share of $1.38 for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

A number of other equities research analysts also recently weighed in on ZLAB. JPMorgan Chase & Co. lifted their price target on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, March 13th. Bank of America reissued a “neutral” rating and issued a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Finally, Scotiabank started coverage on shares of Zai Lab in a report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price objective on the stock.

Zai Lab Stock Up 3.9%

Shares of ZLAB opened at $43.03 on Wednesday. Zai Lab has a 12-month low of $16.01 and a 12-month high of $44.34. The firm has a market capitalization of $4.75 billion, a price-to-earnings ratio of -15.53 and a beta of 0.96. The stock’s 50-day moving average price is $31.50 and its 200 day moving average price is $30.41.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05. The company had revenue of $106.49 million during the quarter, compared to analyst estimates of $118.40 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%.

Insiders Place Their Bets

In related news, insider Frazor Titus Edmondson III sold 4,369 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total value of $156,803.41. Following the transaction, the insider now directly owns 27,217 shares in the company, valued at $976,818.13. This represents a 13.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Rafael Amado sold 3,000 shares of Zai Lab stock in a transaction on Monday, March 17th. The stock was sold at an average price of $38.41, for a total transaction of $115,230.00. Following the sale, the insider now directly owns 30,834 shares of the company’s stock, valued at $1,184,333.94. This represents a 8.87% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 130,207 shares of company stock valued at $3,880,239. 4.96% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zai Lab

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. acquired a new position in shares of Zai Lab during the 4th quarter worth about $46,172,000. Alberta Investment Management Corp boosted its stake in Zai Lab by 42.9% during the 4th quarter. Alberta Investment Management Corp now owns 232,293 shares of the company’s stock worth $6,084,000 after acquiring an additional 69,740 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in Zai Lab by 188.6% during the fourth quarter. Allianz Asset Management GmbH now owns 1,505,866 shares of the company’s stock valued at $39,442,000 after purchasing an additional 984,041 shares during the period. US Bancorp DE increased its stake in Zai Lab by 1,671.9% in the fourth quarter. US Bancorp DE now owns 5,865 shares of the company’s stock valued at $154,000 after purchasing an additional 5,534 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Zai Lab in the fourth quarter worth $1,032,000. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.